NEWSROOM
Insights, events, and firm news for life sciences, pharmaceutical, chemical, and technology innovators.
AI-ASSISTED DRUG DISCOVERY PATENTS: FROM ALGORITHM TO ASSET
AI can accelerate discovery, but it can’t be the inventor. This guide explains how inventorship works in AI-assisted drug discovery, what can go wrong in real workflows, and how in-house teams can document human decision-making to protect patent enforceability and deal readiness.
HOW TO CONDUCT IP DUE DILIGENCE FOR LIFE SCIENCES AND ADVANCED MATERIALS COMPANIES
In life sciences and advanced materials sector, IP due diligence is more than a legal formality; it’s central to valuation, deal viability, and long-term competitiveness. This article outlines a practical roadmap for investors and growth-stage companies to assess IP assets, FTO, risk, and strategy with the rigor these transactions demand.
BIOTECH & PHARMA IP STRATEGIES: LEVERAGING LICENSING, COLLABORATION, AND PLATFORMS BEYOND THE MOLECULES
Intellectual property is the foundation of biotech success. Discover how platform-driven IP strategies, licensing frameworks, and strategic collaborations can amplify valuation, attract investors, and accelerate commercialization. Learn how Hylton Rodic Law helps biotech innovators protect the science, structure the deal, and scale the business.
AI-GENERATED PRIOR ART IN PATENT LAW: HIDDEN RISKS YOU CAN’T IGNORE
AI can accelerate innovation, but it can also introduce synthetic prior art that undermines biotech IP. Explore key risks in operability, public access, and misuse. Learn how to protect your patent filings with expert strategies.
REFLECTIONS FROM MUNICH: A SUMMIT ON LIFE SCIENCES STRATEGY ON IP & EXCLUSIVITY
We’ve just returned from the Life Sciences Strategy Summit in Munich, where Keisha Hylton-Rodic joined global experts to explore divisional patenting and the evolving IP landscape. The conversations were rich, the insights actionable, and the collaboration inspiring.
PHARMA IN A POST-PATENT CLIFF WORLD: PATENT CLIFF STRATEGIES FOR BIOTECH IP PROTECTION
As billions in drug patents expire, the pharmaceutical industry faces a looming patent cliff. Biotech innovators must rethink IP protection to safeguard revenue and innovation. This article explores trade secrets, continuous filings, data ownership, and regulatory exclusivity, strategies that help companies adapt and thrive beyond patent loss.
WHY GREAT PATENTS FAIL: HOW TO BUILD A WINNING IP STORY IN PATENT PORTFOLIO STRATEGY
Strong patents aren't always enough. In biotech and pharma, success hinges on how well your IP tells a story. Learn why great inventions fail in the market, how to craft a compelling IP narrative, and what investors and licensing partners really want to hear. Discover Hylton-Rodic Law’s approach to building winning patent strategies.
RISK MITIGATION IN VENTURE STUDIO DEALS
Intellectual property risks are rising in venture studio models, often unnoticed until it’s too late. This guide explains how to structure IP ownership, avoid earnout traps, and protect trade secrets before deals go sideways. Startups, investors, and studios: don’t skip this legal checklist.
SUNSHINE FRIDAYS, REAL IMPACT
At Hylton-Rodic Law, we believe sustainable legal excellence starts with well-being. That’s why we created Sunshine Fridays, our summer policy where the team logs off at 1:00 PM ET each Friday. It’s part of our broader micro-wellness approach: small, consistent habits that support mental health, fuel focus, and foster a healthier way to practice law.
From quarterly mental health days to birthday PTO and a firmwide holiday week off, our wellness culture isn’t just a perk; it’s our strategy for meaningful, human-centered legal work.
PROTECTING YOUR IDEAS:
Understanding intellectual property is essential for innovators and early-stage businesses. At Hylton-Rodic Law, we’re often asked these key questions, here are our quick answers to help you get started.